Jinxin Fertility Group Ltd
HKEX:1951

Watchlist Manager
Jinxin Fertility Group Ltd Logo
Jinxin Fertility Group Ltd
HKEX:1951
Watchlist
Price: 2.8 HKD -2.1% Market Closed
Market Cap: 7.7B HKD
Have any thoughts about
Jinxin Fertility Group Ltd?
Write Note

Net Margin
Jinxin Fertility Group Ltd

10.7%
Current
13%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
10.7%
=
Net Income
310.8m
/
Revenue
2.9B

Net Margin Across Competitors

Country CN
Market Cap 7.7B HKD
Net Margin
11%
Country US
Market Cap 75.6B EUR
Net Margin
1%
Country US
Market Cap 77.9B USD
Net Margin
1%
Country US
Market Cap 56B USD
Net Margin
1%
Country DE
Market Cap 26B EUR
Net Margin
3%
Country DE
Market Cap 18.9B EUR
Net Margin
-2%
Country US
Market Cap 19.3B USD
Net Margin
3%
Country US
Market Cap 17.7B USD
Net Margin
-2%
Country US
Market Cap 17.1B USD
Net Margin
9%
Country DE
Market Cap 13B EUR
Net Margin
3%
Country US
Market Cap 12.7B USD
Net Margin
7%
No Stocks Found

Jinxin Fertility Group Ltd
Glance View

Market Cap
7.7B HKD
Industry
Health Care

Jinxin Fertility Group Ltd., a prominent player in the assisted reproduction market, has woven its narrative into the tapestry of modern healthcare by addressing a universal yet profoundly personal concern—fertility. Headquartered in China, this company has emerged at the forefront of fertility services, providing a comprehensive suite of offerings that include in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and frozen embryo transfer (FET), among other reproductive technologies. Operating in a market driven by societal shifts such as later-life family planning and increased urbanization, Jinxin Fertility has positioned itself strategically to capitalize on the growing demand for fertility treatments. Through its vast network of clinics across China and in key locations overseas, the company draws a diverse clientele seeking advanced reproductive assistance. What distinguishes Jinxin Fertility Group in this competitive landscape is its blend of cutting-edge technology and high-quality medical expertise. The company invests heavily in research and development to enhance its medical processes, ensuring high success rates and customer satisfaction. This approach not only solidifies its reputation as a trusted provider of fertility solutions but also translates into substantial profitability as clients are willing to invest in reliable and effective treatments for the chance at parenthood. Revenue streams flow from several channels, with core earnings derived from treatment and consultation fees, while ancillary services like genetic testing and cryopreservation contribute additional income. This multifaceted business model not only reinforces Jinxin Fertility’s financial robustness but also underscores its commitment to supporting hopeful parents through every step of their fertility journey.

Intrinsic Value
4.7 HKD
Undervaluation 40%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
10.7%
=
Net Income
310.8m
/
Revenue
2.9B
What is the Net Margin of Jinxin Fertility Group Ltd?

Based on Jinxin Fertility Group Ltd's most recent financial statements, the company has Net Margin of 10.7%.